Researchers have reported encouraging results from an experimental cancer drug called daraxonrasib, which was tested alongside standard chemotherapy in patients with advanced pancreatic cancer.
The early-stage clinical trial found that the combination helped stop tumour growth in approximately 90% of participants. In some patients, tumours became so small that they could no longer be detected through scans.
The findings were presented at an international cancer research conference in Barcelona on November 20, 2026.
Tumour Growth Stopped in Most Participants
The trial involved 61 patients whose pancreatic cancer had spread to other organs. Researchers found that:
- Around 90% experienced halted tumour growth.
- More than 60% had tumours shrink or disappear.
- Approximately 8% had no detectable tumours on CT scans.
- Around 76.6% of participants were alive one year after starting treatment.
How Does the Experimental Treatment Work?
Daraxonrasib belongs to a class of medicines known as KRAS inhibitors. It targets certain mutations that encourage cancer cells to grow and multiply.
In the trial, researchers combined the experimental pill with two established chemotherapy medicines. The results suggest that targeting these mutations could offer a promising direction for pancreatic cancer research.
More Clinical Research Is Needed
Despite the encouraging findings, researchers have cautioned that the results do not establish a cure. The study was relatively small and did not directly compare the combination with chemotherapy alone in a randomised trial.
Larger studies and longer follow-up will be necessary to determine whether the treatment can improve survival and provide lasting benefits.
The findings nevertheless represent an important development in research into one of the most difficult cancers to treat.
